Patents by Inventor Toshio Nishihara

Toshio Nishihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190030149
    Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
    Type: Application
    Filed: October 17, 2018
    Publication date: January 31, 2019
    Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Chiang Jia LI, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
  • Patent number: 9765114
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: September 19, 2017
    Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Toshio Nishihara, Masashi Gotoh
  • Publication number: 20160168197
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Application
    Filed: February 26, 2016
    Publication date: June 16, 2016
    Applicants: International Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Toshio NISHIHARA, Masashi Gotoh
  • Publication number: 20160114019
    Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
    Type: Application
    Filed: December 30, 2015
    Publication date: April 28, 2016
    Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
  • Patent number: 9273148
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: March 1, 2016
    Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Toshio Nishihara, Masashi Gotoh
  • Patent number: 9248173
    Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: February 2, 2016
    Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
  • Patent number: 9181302
    Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: November 10, 2015
    Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
  • Publication number: 20150238587
    Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
    Type: Application
    Filed: May 7, 2015
    Publication date: August 27, 2015
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
    Inventors: Chiang Jia LI, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
  • Publication number: 20140046036
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Application
    Filed: September 10, 2013
    Publication date: February 13, 2014
    Applicants: International Institute of Cancer Immunology, Inc., Dainippon Sumitomo Pharma Co., Ltd., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Toshio NISHIHARA, Masashi Gotoh
  • Patent number: 8575308
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: November 5, 2013
    Assignees: International Institute of Cancer Immunology, Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Toshio Nishihara, Masashi Gotoh
  • Publication number: 20110229506
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Application
    Filed: March 22, 2011
    Publication date: September 22, 2011
    Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: TOSHIO NISHIHARA, MASASHI GOTOH
  • Patent number: 7939627
    Abstract: A compound of formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond; R1 is a hydrogen atom; R2 is a hydroxy group; R3 is a hydrogen atom, alkyl group, amino group substituted alkylcarbonylamino; R4 is a hydrogen atom, alkyl group, carboxy group a group of formula (2): wherein W is an amino acid residue; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: May 10, 2011
    Assignees: International Institute of Cancer Immunology, Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Toshio Nishihara, Masashi Gotoh
  • Publication number: 20100062010
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Application
    Filed: November 29, 2006
    Publication date: March 11, 2010
    Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Toshio Nishihara, Masashi Gotoh
  • Patent number: 6936736
    Abstract: A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.; R4 and R5 are independently hydrogen atom or optionally substituted alkyl; R6 is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: August 30, 2005
    Assignee: Sumitomo Manufacturing Company Limited
    Inventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
  • Publication number: 20020147204
    Abstract: A compound of the formula: 1
    Type: Application
    Filed: March 26, 2002
    Publication date: October 10, 2002
    Applicant: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
  • Patent number: 6384033
    Abstract: A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.; R4 and R5 are independently hydrogen atom or optionally substituted alkyl; R6 is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: May 7, 2002
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Kazuhito Ikeda, Tohru Tatsuno, Hiroki Ogo, Toshio Nishihara, Tatsuya Fujibayashi, Ryu Nagata
  • Patent number: 6293080
    Abstract: A sewing thread for a leather product composed of fibers attached with a highly water absorbing powdery material on the surface of the fibers, in a ratio of 5 weight % or more based on the weight of the fibers, and a leather product, with excellent water-proof property, prepared by using the same thread.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: September 25, 2001
    Assignee: Teijin Limited
    Inventors: Toshio Nishihara, Tuyoshi Torikai
  • Patent number: 6048854
    Abstract: The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.
    Type: Grant
    Filed: September 25, 1997
    Date of Patent: April 11, 2000
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Yoshiharu Ikeda, Yasuyuki Ueki, Hisakazu Kishimoto, Toshio Nishihara, Yumiko Kamikawa
  • Patent number: 5759991
    Abstract: The invention provides human- or rat-derived neurotrophic peptides and derivatives thereof, precursor peptides thereof, genes encoding the same, transformants containing recombinant expression vectors bearing the genes, and compositions comprising as an effective ingredient these neurotrophic peptides or derivatives thereof. The neurotrophic peptide or its derivatives of the present invention have a neurotrophic activity and are useful for the treatment of neuro-degenerative disorders and dementia.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: June 2, 1998
    Assignees: Sumitomo Pharmaceutical Company, Limited., Kosei Ojika, Masahiko Yamamoto
    Inventors: Naoki Tohdoh, Shin-ichiro Tojo, Shin-ichi Kojima, Yasuyuki Ueki, Toshio Nishihara, Nobuyuki Fukushima, Tsunemasa Irie, Keiichi Ono, Hideo Agui, Kosei Ojika
  • Patent number: 5707994
    Abstract: The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: January 13, 1998
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Yoshihara Ikeda, Yasuyuki Ueki, Hisakazu Kishimoto, Toshio Nishihara, Yumiko Kamikawa